S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Ocular Therapeutix Stock Forecast, Price & News

+0.07 (+1.74%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
472,611 shs
Average Volume
645,862 shs
Market Capitalization
$313.95 million
P/E Ratio
Dividend Yield
Price Target

Ocular Therapeutix Stock Forecast (MarketRank)

Analyst Rating
3.25 Rating Score
334.0% Upside
$17.75 Price Target
Short Interest
4.61% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($0.81) to ($0.70) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.17 out of 5 stars

Medical Sector

402nd out of 1,428 stocks

Pharmaceutical Preparations Industry

187th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

Ocular Therapeutix logo

About Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

OCUL Stock News Headlines

Ocular Therapeutix Tops Q1 EPS by 4c
Recap: Ocular Therapeutix Q4 Earnings
Ocular Therapeutix Q4 2021 Earnings Preview
Ocular Therapeutix, Inc. Common Stock (OCUL)
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$-6.55 million
Pretax Margin


Sales & Book Value

Annual Sales
$43.52 million
Book Value
$1.15 per share


Free Float
Market Cap
$313.95 million

Ocular Therapeutix Frequently Asked Questions

Should I buy or sell Ocular Therapeutix stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ocular Therapeutix stock.
View analyst ratings for Ocular Therapeutix
or view top-rated stocks.

What is Ocular Therapeutix's stock price forecast for 2022?

4 brokerages have issued 12 month target prices for Ocular Therapeutix's stock. Their OCUL stock forecasts range from $10.00 to $29.00. On average, they expect Ocular Therapeutix's stock price to reach $17.75 in the next year. This suggests a possible upside of 334.0% from the stock's current price.
View analysts' price targets for Ocular Therapeutix
or view top-rated stocks among Wall Street analysts.

How has Ocular Therapeutix's stock performed in 2022?

Ocular Therapeutix's stock was trading at $6.97 on January 1st, 2022. Since then, OCUL shares have decreased by 41.3% and is now trading at $4.09.
View the best growth stocks for 2022 here

When is Ocular Therapeutix's next earnings date?

Ocular Therapeutix is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Ocular Therapeutix

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) issued its quarterly earnings data on Monday, May, 9th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.03. The biopharmaceutical company had revenue of $13.19 million for the quarter, compared to the consensus estimate of $15.03 million. Ocular Therapeutix had a negative net margin of 45.00% and a negative trailing twelve-month return on equity of 26.50%.
View Ocular Therapeutix's earnings history

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the following people:
  • Mr. Antony Mattessich, Pres, CEO & Director (Age 55, Pay $1.04M) (LinkedIn Profile)
  • Mr. Donald Notman Jr., Chief Financial Officer
  • Dr. Michael H. Goldstein M.M., M.D., M.B.A., Pres of Ophthalmology & Chief Medical Officer (Age 55, Pay $735.75k)
  • Dr. Peter K. Jarrett Ph.D., Chief Scientific Officer (Age 65)
  • Mr. Philip C. Strassburger, Gen. Counsel (Age 62)
  • Mr. William H. Ransone II, VP of Global Sales & Marketing
  • Ms. Tracy Smith, VP of HR
  • Mr. Scott Corning, Sr. VP of Commercial
  • Mr. Christopher G. White, Chief Bus. Officer (Age 60)
  • Dr. Rabia Gurses Ozden M.D., Sr. VP of Clinical Devel. (Age 53)

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), (CELG), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

How do I buy shares of Ocular Therapeutix?

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $4.09.

How much money does Ocular Therapeutix make?

Ocular Therapeutix (NASDAQ:OCUL) has a market capitalization of $313.95 million and generates $43.52 million in revenue each year. The biopharmaceutical company earns $-6.55 million in net income (profit) each year or ($0.930010) on an earnings per share basis.

How many employees does Ocular Therapeutix have?

Ocular Therapeutix employs 228 workers across the globe.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The official website for Ocular Therapeutix is www.ocutx.com. The biopharmaceutical company can be reached via phone at (781) 357-4000, via email at chris.brinzey@westwicke.com, or via fax at 781-357-4001.

This page (NASDAQ:OCUL) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.